Research
Clinical trials
Every amyloidosis study now recruiting, about to open, or enrolling by invitation, anywhere in the world, listed straight from ClinicalTrials.gov and refreshed every day.
Information, not medical advice. The Alliance does not run these studies and cannot enrol you in one. If a trial looks relevant, discuss it with the doctor who follows your amyloidosis.
Recruiting and upcoming studies
The list covers AL, ATTR and AA amyloidosis as well as cerebral amyloid angiopathy. Each card says where the study stands: open to anyone who meets its criteria, not yet open, or restricted to people the investigators invite. Studies that close simply leave the list.
Showing 73–84 of 208 trials
Enrolling by invitationNot specified
124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome (opens on ClinicalTrials.gov)
This clinical trial will use the amyloid-binding radiotracer, 124I-evuzamitide, to potentially detect amyloid, in the heart and elsewhere, in patients who have a history…
- Study
- Interventional (treatment)
- Phase
- Phase 2
- Sponsor
- University of Tennessee Graduate School of Medicine
Recruiting in: United States
NCT06907849Updated 21 July 2026
RecruitingNot specified
CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study (opens on ClinicalTrials.gov)
Exercise training in patients with heart failure and preserved ejection fraction (HFpEF) has been associated with an improvement in cardiorespiratory fitness and quality of…
- Study
- Interventional (treatment)
- Sponsor
- Wake Forest University Health Sciences
Recruiting in: United States
NCT06096675Updated 21 July 2026
RecruitingATTR (transthyretin)
Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis (opens on ClinicalTrials.gov)
CONCERTO is a retrospective, observational, multicentric and single-arm study to perform an external validation of the cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named…
- Study
- Observational (registry, imaging)
- Sponsor
- Idoven 1903 S.L.
Recruiting in: FranceGermanySpainUnited Kingdom+1
NCT06978660Updated 20 July 2026
RecruitingAL (light chain)
The Norwegian Immunotherapy in Multiple Myeloma Study (opens on ClinicalTrials.gov)
The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in…
- Study
- Observational (registry, imaging)
- Sponsor
- St. Olavs Hospital
Recruiting in: Norway
NCT06855121Updated 20 July 2026
RecruitingAL (light chain)
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis (opens on ClinicalTrials.gov)
The study aims to evaluate the efficacy and safety of belantamab mafodotin in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly…
- Study
- Interventional (treatment)
- Phase
- Phase 2
- Sponsor
- GlaxoSmithKline
Recruiting in: AustraliaUnited States
NCT07224672Updated 17 July 2026
Not yet recruitingAL (light chain)
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis (opens on ClinicalTrials.gov)
The purpose of this study is to evaluate the efficacy and safety of NXC-201 compared with Dara-CyBorD (daratumumab-cyclophosphamide-bortezomib-dexamethasone) in the treatment of newly diagnosed…
- Study
- Interventional (treatment)
- Phase
- Phase 3
- Sponsor
- Nexcella Inc.
No study locations listed yet
NCT07709715Updated 16 July 2026
RecruitingAL (light chain)
Teclistamab-Daratumumab in AL Amyloidosis (opens on ClinicalTrials.gov)
The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis. The study treatment is divided into…
- Study
- Interventional (treatment)
- Phase
- Phase 2
- Sponsor
- Rajshekhar Chakraborty, MD
Recruiting in: United States
NCT07110844Updated 13 July 2026
RecruitingATTR (transthyretin)AL (light chain)
Hungarian National Systemic Amyloidosis Registry (opens on ClinicalTrials.gov)
This registry is an observational, multicenter, retrospective and prospective, non-pharmacological study designed to collect and analyze data from patients with systemic amyloidosis treated in…
- Study
- Observational (registry, imaging)
- Sponsor
- Semmelweis University
Recruiting in: Hungary
NCT07689331Updated 8 July 2026
RecruitingATTR (transthyretin)
A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting (opens on ClinicalTrials.gov)
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a serious and life-threatening condition where a protein called transthyretin (TTR) misfolds and builds up as amyloid fibrils in…
- Study
- Observational (registry, imaging)
- Sponsor
- Bayer
Recruiting in: Germany
NCT07235462Updated 7 July 2026
RecruitingAL (light chain)
Optimize First-line Treatment for AL Amyloidosis With t (11; 14) (opens on ClinicalTrials.gov)
Achievement of complete hematologic response (CHR) is vital for systemic AL amyloidosis. Currently, the CHR rate of daratumumab, bortezomib, and dexamethasone (DBD) is close…
- Study
- Interventional (treatment)
- Sponsor
- Jin Lu, MD
Recruiting in: China
NCT06192979Updated 7 July 2026
RecruitingAL (light chain)
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. (opens on ClinicalTrials.gov)
Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light…
- Study
- Interventional (treatment)
- Phase
- Phase 1
- Sponsor
- Alexion Pharmaceuticals, Inc.
Recruiting in: CanadaUnited KingdomUnited States
NCT07081646Updated 2 July 2026
RecruitingAL (light chain)
DapagliFLOzin in Renal AL Amyloidosis (FLORAL) (opens on ClinicalTrials.gov)
The goal of this clinical trial is to learn if an oral drug called dapagliflozin is safe and can reduce high protein levels in…
- Study
- Interventional (treatment)
- Phase
- Phase 2
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Recruiting in: United States
NCT06420167Updated 26 June 2026
This list only covers amyloidosis studies that are open or about to open. The registry holds every study, including those already completed.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). List last retrieved on 25 September 2026. clinicaltrials.gov
Not sure where to start?
Our member associations know the teams running these studies in their own country, and can help you prepare the conversation with your doctor.